On January 19, during an online investor exchange session for Guangzhou Wondfo Biotech Co.,Ltd. (hereinafter referred to as "Wondfo Biotech"), a relevant company representative stated that since its listing in 2015, Wondfo Biotech has consistently regarded innovation as the primary driver for business development. The company is closely monitoring the transformative impact of AI on healthcare and is strategically deploying resources in AI healthcare by leveraging its existing strengths in the laboratory diagnostics sector.
Starting in 2018, the company entered the digital pathology field and, through participation in fund investments, addressed gaps in its imaging sector layout. Currently, its investment Yizhun Intelligent has established a leading position in radiology and ultrasound, particularly in ultrasound, enabling the company to construct a multi-modal diagnostic architecture encompassing imaging, pathology, and laboratory diagnostics.
For its out-of-hospital business, the company continuously enhances brand influence, operational efficiency, and innovation capability through AI applications, noting that healthcare reform policies have no impact on its to-C business. Looking ahead, the company plans to increase AI investments through a combination of mergers and acquisitions and internal growth, integrating to-B and to-C approaches, and fostering synergies within the AI ecosystem to provide the market with more valuable medical tools and products.
Addressing investor concerns about whether the core business would see significant improvement in 2026 after facing performance pressure in 2025, and what bright spots could be anticipated in domestic and overseas operations, the company representative indicated that in 2025, to adapt to industry changes, the company adjusted its operational strategies. These adjustments included divesting risky assets and improving operational quality, which led to a significant decline in the profit statement; however, the corresponding measures to enhance operational quality have yielded substantive results.
Looking forward to 2026, domestic business is expected to show good recovery based on the low comparative base of 2025. Overseas business growth projections are favorable, and the company is confident about its performance development in 2026.
Since 2018, Wondfo Biotech has begun its strategic layout in AI healthcare, forming an AI healthcare ecosystem that concurrently emphasizes "M&A, hospital-end, and C-end." The goal is to achieve more regulatory approvals and breakthroughs in business models, aiming to become a leading enterprise in China's AI healthcare sector in the medium to long term.
At its own operational level, for the hospital segment, the company innovatively developed the intelligent testing AI platform "Wondfo Smart Test," which is equipped with multiple AI applications for various testing scenarios. It has already been implemented in numerous areas including coagulation disorders, oncology, women and children's diseases, and critical care.
For the C-end/consumer segment, the Wondfo Health mini-program has been launched. It can automatically identify test results for respiratory, digestive tract, and blood-borne infectious diseases using AI and supports the creation of personal health records, helping to drive growth in the consumer-end business.
In the future, AI holds immense potential for development in diagnostics. Wondfo Biotech will continue to enhance its own capabilities to seize the opportunities presented by AI applications in upgrading diagnostic and treatment capacities.
Comments